CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 156 enrolled
Drug / intervention
AIC316 +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01047540
NCT01047540Phase 2Completed
CompareCT.gov

A Double-blind Randomized Placebo Controlled Dose-finding Trial to Investigate Different Doses of a New Antiviral Drug in Subjects With Genital HSV Type 2 Infection

AiCuris Anti-infective Cures AG·interventional·Posted Jan 13, 2010·Updated Apr 21, 2023

In Brief

A Phase 2 clinical trial evaluating AIC316 and Placebo for HSV-2. Completed, enrolled 156 participants across 6 sites.

Detailed Summary

The aim of the study is to find out whether AIC316 is safe and efficacious for the prevention of reactivation of genital herpes

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHSV-2
CountriesUnited States
CollaboratorsFHI 360

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 13, 2010
Enrollment StartMar 1, 2010
Primary CompletionDec 1, 2010
Study CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 16.5 years ago

Interventions

AIC316drug

Oral administration

AIC316drug

Oral administration

AIC316drug

Oral administration

AIC316drug

Oral administration

Placebodrug

Oral administration